Read More

Enveric Biosciences nabs patent for “next-gen” psilocin prodrug

Enveric Biosciences (NASDAQ: ENVB) has received a U.S. patent for its drug candidate EB-002, the company announced Wednesday. The patent (No. 11,945,778) covers methods of treatment for a range of brain neurological disorders, including sleep disorders, depression, substance-related disorders, and headaches, the company said. Those conditions involve similar neurotransmitter systems. …